Data from EMA (European Medicines Agency) - Curated by Toby Galbraith - Last updated 19 May 2017

Indication(s)

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Visit Oral Anticoagulation Reversal

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

Visit Cushing's Syndrome

Related Content

More information

Category Value
Agency product number EMEA/H/C/003825
Orphan designation No
Date First Approved 18-02-2016
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Bayer Pharma AG
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions